The quest for a non-pharmaceutical therapy for hypertension suffered a setback recently with the publication of two studies on renal denervation (RDN).
Both articles appeared in the Journal of the American College of Cardiology, and both reported on trials that showed the procedure did not lower blood pressure.
But in an accompanying editorial, Vivek Reddy, MD, and Jeffrey Olin, DO, said they have critical questions about those studies that need to be answered before RDN therapy is written off.
Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) is a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.
Renal denervation does not reduce ambulatory blood pressure in patients with resistant hypertension, and denervation procedures may miss targets, according to two studies published online Sept. 8 in the Journal of the American College of Cardiology.
The association between obesity and the development of hypertension appears to be driven specifically by visceral adiposity, according to research published in the Sept. 9 issue of the Journal of the American College of Cardiology.
The high-density lipoprotein mimetic peptide 4F can successfully rescue advanced pulmonary hypertension in rodent models, according to a study published in Circulation.
Hypertension has long been linked to obesity, but a new study shows that where that fat is matters.
A team of researchers at University of Texas Southwestern Medical Center in Dallas, TX conclude that when that fat is in the viscera—as opposed to accumulating under the skin—there is a strong chance patients will develop hypertension.